Reich Samuel J 4

What Happened Samuel J. Reich, CEO and director of SAB Biotherapeutics (SABS), received a grant of 4,800,000 stock options on February 3, 2026. The Form 4 shows the award as an acquisition with a reported price of $0.00 (no cash exchanged in the grant). This is an equity award (options), not an open-market purchase or sale of shares.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (timely filing).
• Reported amount: 4,800,000 options; acquisition price shown as $0.00 (grant).
• Vesting: Options vest over four years — 1/4 vests on the one-year anniversary, remaining 3/4 vest pro rata monthly in 36 equal installments (per filing footnote).
• Plan: Options issued under the Issuer’s 2021 Omnibus Equity Incentive Plan (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding sale, or cashless exercise noted in the provided details.

Context This was a standard equity award (options) to an executive; options give the right to purchase shares in the future subject to vesting and exercise terms. The grant does not represent an immediate purchase or sale of shares and does not by itself indicate a current change in Reich’s shareholdings until options are vested and exercised.